The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | The PANGEA model: improving risk stratification in multiple myeloma
In this video, Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, discusses the PANGEA model which uses continuous variables to predict the risk of progression for patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. Ms Cowan first explains how the PANGEA model has improved and compares it to the current gold standard, which is the 20/2/20 model and the 2014 IMWG MGUS criteria. Following this, Ms Cowan details the additional variables and statistical analyses used in the PANGEA model, and how these factors improve the ability of this model to predict a patient’s risk of progression. Ms Cowan then discusses recent research which focuses on how to examine risk of progression without the use of bone marrow biopsies, and the various algorithms used in the PANGEA model. To conclude, Ms Cowan highlights the ability of this model to be used on an individual basis, and the role it will have in improving risk progression for patients in the future. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
